ImmunoPrecise Announces Expansion into Humanizing Technologies

ImmunoPrecise Antibodies (TSXV:IPA) announced its working towards delivering humanized monoclonal antibodies.
As quoted in the press release:

ImmunoPrecise has conducted research and development activities using transgenic mice and rats to successfully deliver humanized monoclonal antibodies to drug development companies this past quarter.  Importantly, these projects served to demonstrate the value of applying the Company’s proprietary Rapid Prime methodology in transgenic animals.
“We are very pleased with the success of our Rapid Prime methodology in these animals,” said Teri Otto, Head of Laboratory Services at ImmunoPrecise.  “We delivered a large number of high-quality clones to our customers in a short time frame.  It is extremely important to emphasize that our consistent high quality and superior speed is crucial to the clientele we serve and one of the keys to unlocking new and repeat business.”
In addition, ImmunoPrecise has begun collaborating with companies that provide next generation sequencing.  Next generation sequencing allows scientists to take a rabbit monoclonal antibody generated by ImmunoPrecise, use powerful bioinformatics to compare its sequence to a human antibody reference library, and then genetically engineer it to be more human-like.  ImmunoPrecise’s goal is to continue working with companies providing humanizing platforms based on transgenic animals as well as collaborate with companies applying bioinformatics in humanization. These strategies will allow ImmunoPrecise to offer clients a broad choice of potential humanizing solutions.

Click here to read the full press release.

Source: www.newswire.ca